| Karen West-ellis, APRN | |
|
2084 N 1700 W, Suite A, Layton, UT 84041 | |
| (801) 773-8644 | |
| (801) 773-9828 |
| Full Name | Karen West-ellis |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Pediatrics |
| Location | 2084 N 1700 W, Layton, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144200171 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0200X | Nurse Practitioner - Pediatrics | 197691-4405 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karen West-ellis, APRN 2086 N 1700 W, Suite C, Layton, UT 84041 Ph: (801) 773-8644 | Karen West-ellis, APRN 2084 N 1700 W, Suite A, Layton, UT 84041 Ph: (801) 773-8644 |
News Archive
New research has uncovered the risk factors for Fijians carrying a pneumonia-causing bacteria.
Using a large transfusion database, with data going back to the 1960s, researchers at Karolinska Institutet have been able to identify 44 donors and 1,180 transfused patients likely to be infected with hepatitis C, who are still alive and who remain undiagnosed.
Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's investigational new drug application.
A Massachusetts General Hospital research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men. In the Dec. 1 issue of the Journal of Infectious Diseases the investigators report finding that HIV-infected women had a greater prevalence of the type of coronary artery plaque most vulnerable to rupture than did uninfected women.
The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition.
› Verified 1 days ago
Jennifer C Green, MSN, APRN, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 838 E 625 S, Layton, UT 84041 Phone: 801-725-5595 | |
Shae Francom, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2075 University Park Blvd, Layton, UT 84041 Phone: 801-779-6200 | |
Jonathan D Wilson, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3225 W Gordon Ave Ste 1, Layton, UT 84041 Phone: 801-397-6150 Fax: 801-397-6151 | |
Elizabeth Regan Harwell, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 934 S Main St, Layton, UT 84041 Phone: 801-773-7060 Fax: 801-336-1787 | |
Emily L Meyerhoffer, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 201 W Layton Pkwy Ste 4c, Layton, UT 84041 Phone: 801-475-3100 Fax: 801-475-3101 | |
Whitney Nicole Jones, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1365 E Petunia Ct, Layton, UT 84040 Phone: 801-949-3802 | |
Steve D Mayer, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1916 N 700 W Ste 250, Layton, UT 84041 Phone: 801-479-0312 Fax: 801-479-3364 |